FDA Launches "Regulatory Assaults" on Producers of CBDs and Hemp Oil Extracts

cbds-and-hemp-oil-extracts One need not look far to see the vital impact that CBDs and hemp oil extracts have had on legitimizing the medical marijuana industry. Treating a wide range of illnesses from epileptic seizures in small children to side effects associated with HIV infection in adults, CBDs have demonstrated time and time again their powerful potential as a preferred alternative treatment to synthetic pharmaceuticals. Due mainly to the success of CBDs however, and the potential for Big Pharma to capture a substantial portion of market share with patents that only they can obtain, the revolving door of the Food and Drug Administration recently launched a series of aggressive regulatory responses towards the companies that supply and distribute this medicine. cbds-and-hemp-oil-extracts Lacking outright in justice, this latest denouncement of CBDs by the FDA, shows not only the monopolistic stranglehold that Big Pharma has on the industry, but also its cold and calculated nature in attempting to patent and take credit for a natural medicine (plant molecules) , which they continue to fiercely relegate via their website, despite countless testimonies from patients claiming its superior value when compared to conventional over the counter drugs.

CBDs and Hemp Oil Extracts Save Lives

Not convinced about the power of CBDs as a natural medicine? Just ask the parents of Katherine King, whose daughter had no other option then to start a strict regimen of CBD/THC oil therapy from their local cannabinoid collective after Doctors literally "gave up" trying to cure her DIPG (Diffuse Intrinsic Pontine Glioma) with impotent pharma drugs and radiation. katherine-king-cbds-and-hemp-oil-extracts Or ask the parents of Cyndimae Meehan who tried 23 anti-epileptic pharmaceutical drugs for the expected treatment of their daughter's Dravet Syndrome before realizing that these drugs were ineffectual when compared to the healing properties of CBDs. Still not convinced? Ask the other 1.2 million medical marijuana patients in the 24 legalized states what their lives would be like without CBD and THC derived products to medicate their conditions ranging from depression to cancer. The numbers don't lie and the testimonies are real!

The Monopolistic Stranglehold of Big Pharma

In spite of their miraculous power and healing capabilities, CBD manufacturers and the companies that market them have come under recent and intense scrutiny from the Food and Drug Administration, which has essentially issued an all out BAN on CBDs (plant molecules) being sold as dietary supplements, unless of course, you're one of its Big Pharma cronies. According to its website, the "FDA has concluded that cannabidiol products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the FD&C Act", given that CBDs are still being “authorized for investigation as a new drug”. Under this recent statute, the FDA emphasizes that unapproved CBDs and cannabidiol derived products are "illegal"  and thus subject to legal consequences, even in states that have legalized marijuana. cbds-and-big-pharma Just last month for example, eight companies that supply and market CBDs and CBD derived products were issued warning letters asking them to discontinue their marketing and selling of CBDs or be met with legal action. "The letters are all fairly similar and criticize health claims made by the company as supplements.  Unless the product was marketed before GW Pharma (NASDAQ: GWPH) published clinical trials, the companies can't make health claims."

The Power of Patents

To date, there are hundreds if not thousands of producers that make CBD derived products across legalized states in the U.S. By stating that only one company, GW Pharmaceuticals, has the exclusive right to to test their CBD products (Sativex and Epidiolex) when literally thousands of potential companies could have applied for this testing, shows not only the plausible collusive efforts of the FDA and GW Pharmaceuticals, but also the monopolistic interest in having that one company patent the drug. Making matters even more perplexing, the U.S. government already has a patent for cannabinoid based medicine assigned to the United States of America by the Department of Health and Human Services. The patent states: “Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”  red-flag Stating that "cannabis has no medicinal value" while the U.S. government has held US Patent 6630507 , since 2003, should come as an immediate red flag that the FDA has ulterior motives in analyzing the medicinal value of cannabis. Rather then regulating CBDs in the same way as other standardized medicine, the FDA is criminalizing one of the most miraculous medicines of today and handing the key over to pharmaceutical companies. With this move, the FDA is nonchalantly spitting in the face of the medical marijuana industry and its countless patients that truly need this miracle medicine. These new regulations will, in essence, do more immediate harm to the public than good by making it even harder for patients to obtain the medicine that many cannot live a quality life without. The question is: what are you going to do about it?
Previous article Buying Marijuana May Be Protected in Oregon

Comments

Evalyn Lenarz - December 7, 2018

At around 19:58 CET this evening, five of Gaia’s eight thrusters will be commanded to fire an automated burn lasting almost two hours. It’s a critical manoeuvre meant to bring Gaia onto its planned operational orbit about the L2 Lagrange point (a second, smaller, burn on 14 January will complete the process).

Leave a comment

* Required fields